These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20570860)

  • 1. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
    Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
    Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
    Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
    Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bim is a suppressor of Myc-induced mouse B cell leukemia.
    Egle A; Harris AW; Bouillet P; Cory S
    Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6164-9. PubMed ID: 15079075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.
    Anderton E; Yee J; Smith P; Crook T; White RE; Allday MJ
    Oncogene; 2008 Jan; 27(4):421-33. PubMed ID: 17653091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.
    Piazza R; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Pelosi G; Gambacorti-Passerini C
    Neoplasia; 2013 May; 15(5):511-22. PubMed ID: 23633923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression.
    Mérino D; Strasser A; Bouillet P
    Oncogene; 2012 Jul; 31(28):3392-6. PubMed ID: 22081075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
    Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
    PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
    Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
    Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
    Mestre-Escorihuela C; Rubio-Moscardo F; Richter JA; Siebert R; Climent J; Fresquet V; Beltran E; Agirre X; Marugan I; Marín M; Rosenwald A; Sugimoto KJ; Wheat LM; Karran EL; García JF; Sanchez L; Prosper F; Staudt LM; Pinkel D; Dyer MJ; Martinez-Climent JA
    Blood; 2007 Jan; 109(1):271-80. PubMed ID: 16960149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
    De Bruyne E; Bos TJ; Schuit F; Van Valckenborgh E; Menu E; Thorrez L; Atadja P; Jernberg-Wiklund H; Vanderkerken K
    Blood; 2010 Mar; 115(12):2430-40. PubMed ID: 20086250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
    Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
    Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
    Ni F; Huang X; Chen Z; Qian W; Tong X
    Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
    Harrington CT; Sotillo E; Robert A; Hayer KE; Bogusz AM; Psathas J; Yu D; Taylor D; Dang CV; Klein PS; Hogarty MD; Geoerger B; El-Deiry WS; Wiels J; Thomas-Tikhonenko A
    Leukemia; 2019 Oct; 33(10):2429-2441. PubMed ID: 30914792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance.
    Zantl N; Weirich G; Zall H; Seiffert BM; Fischer SF; Kirschnek S; Hartmann C; Fritsch RM; Gillissen B; Daniel PT; Häcker G
    Oncogene; 2007 Oct; 26(49):7038-48. PubMed ID: 17486061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.
    Mazzoccoli L; Robaina MC; Apa AG; Bonamino M; Pinto LW; Queiroga E; Bacchi CE; Klumb CE
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):483-497. PubMed ID: 29318382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.